Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Pediatric Hematology/Oncology
•
Internal Medicine
•
Rheumatology
•
Hematology
•
Pediatric Hematology
•
Lupus nephritis
•
Antiphospholipid Syndrome
•
Nephrology
•
Glomerulonephritis
•
Anticoagulation
In patients with lupus nephritis, and MAHA with positive anti-phospholipid autoantibodies, what are the considerations to use or not use anti-coagulation therapy?
Related Questions
Can anti-cardiolipin or anti-beta-2 glycoprotein antibodies cause prolonged PTT in the absence of a lupus anticoagulant?
Do you ever combine voclosporin and belimumab in the treatment of lupus nephritis?
How do you manage arthritis resulting from deferiprone in transfusion dependent thalassemia?
How do you approach the management of patients with suspected membranous lupus nephritis who are found to have positive PLA2R antibodies?
How do you determine duration of therapy for patients who have responded well to voclosporin therapy?
How would you approach pursuing a kidney biopsy in a patient with suspected lupus nephritis who is on warfarin for antiphospholipid antibody syndrome?
What drives you to choose voclospsorin over tacrolimus given the substantially higher cost?
Do you avoid ESA use in patients with anemia and chronic kidney disease who also have APLS and risk for thrombosis?
How would you approach management of a patient with ESRD on the transplant list who is found to have high titer APS labs (ACL, B2GP1, LAC)?
How do you approach discussing the pill burden of voclosporin with patients who already have to take a regimen such as MMF+HCQ+ACEi and possibly more?